Acadia Pharmaceuticals Inc.— Sankey Diagram
Quarterly mode · period ending 2025-12-31 · SEC EDGAR
ComparingFY2025 (Q4) vs FY2024 (Q4)
Revenue
$284M
↑+9.4% +$24Mvs FY2024 (Q4)
Gross Profit
$258M
↑+8.4% +$20Mvs FY2024 (Q4)
Operating Income
$17M
↓-88.7% -$136Mvs FY2024 (Q4)
Net Income
$9M
↓-93.7% -$135Mvs FY2024 (Q4)
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 (Q4) | FY2024 (Q4) |
|---|---|---|
| Revenue | $284M | $260M |
| COGS | $26M | $22M |
| Gross Profit | $258M | $238M |
| R&D | $85M | $84M |
| SG&A | $156M | $0 |
| D&A | $0 | $0 |
| Other OpEx | $0 | $0 |
| Operating Income | $17M | $154M |
| Interest Exp. | $8M | $7M |
| Other Non-Op | $0 | $0 |
| Pretax Income | $9M | $146M |
| Tax | $0 | $3M |
| Net Income | $9M | $144M |
QuarterCharts · SEC EDGAR data · ACAD · Comparing FY2025 (Q4) vs FY2024 (Q4)